| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |